Search

Your search keyword '"Židzik, Jozef"' showing total 26 results
Start Over Author "Židzik, Jozef"
26 results on '"Židzik, Jozef"'

3. Factors associated with all-cause mortality following endovascular abdominal aortic aneurysm repair

Author

Rašiová, Mária, primary, Koščo, Martin, additional, Moščovič, Matej, additional, Pavlíková, Veronika, additional, Habalová, Viera, additional, Židzik, Jozef, additional, Tormová, Zuzana, additional, Hudák, Marek, additional, Bavoľárová, Marta, additional, Perečinský, Slavomír, additional, Dekanová, Lucia, additional, and Tkáč, Ivan, additional

Published
2023
Full Text
View/download PDF

13. Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors

Author

Űrgeová, Anna, primary, Javorský, Martin, additional, Klimčáková, Lucia, additional, Židzik, Jozef, additional, Šalagovič, Ján, additional, Hubáček, Jaroslav A, additional, Doubravová, Pavlina, additional, Gotthardová, Ivana, additional, Kvapil, Milan, additional, Pelikánová, Terezie, additional, Tkáč, Ivan, additional, and Yaluri, Alena Stančáková, additional

Published
2020
Full Text
View/download PDF

16. An Association Between rs7635818 Polymorphism Located on Chromosome 3p12.3 and the Presence of Abdominal Aortic Aneurysm.

Author

RAŠIOVÁ, Mária, HABALOVÁ, Viera, ŽIDZIK, Jozef, KOŠČO, Martin, FARKAŠOVÁ, Ľudmila, MOŠČOVIČ, Matej, HUDÁK, Marek, JAVORSKÝ, Martin, and TKÁČ, Ivan

Subjects
ABDOMINAL aortic aneurysms, CHROMOSOME polymorphism, GENOME-wide association studies, DUPLEX ultrasonography, AORTA, GENETIC models, CHROMOSOME inversions
Abstract

The association between gene variant rs7635818 located on chromosome 3p12.3 and abdominal aortic aneurysm (AAA) was not unambiguously determined by the results of genome-wide association studies. The aim of our study was to examine this possible association in the Slovak population, with respect to the presence and severity of AAA. A cross-sectional study was conducted between August 2016 and March 2020. The study included 329 participans, 166 AAA patients and a control group of 163 subjects without confirmed AAA with comparable distribution of genders. The anteroposterior diameter of the abdominal aorta was determined by duplex ultrasonography. AAA was defined as subrenal aortic diameter = 30 mm. DNA samples were genotyped using real-time polymerase chain reaction and subsequent high-resolution melting analysis in presence of unlabelled probe. Genetic models studying the possible association were adjusted to age, sex, smoking, arterial hypertension, diabetes mellitus, creatinine and body mass index (BMI) in multivariate analysis. In the additive model, presence of each C-allele of rs7635818 polymorphism was associated with an almost 50 % increase in probability of developing AAA (OR 1.49; 95 % CI 1.06=2.08; p=0.020). Compared to GG homozygotes, CC homozygotes had more than two times higher risk of developing AAA (OR 2.23; 95 % CI 1.14=4.39; p=0.020). The risk of AAA was also in the recessive model higher for CC homozygotes compared to G-allele carriers (GC/GG) (OR 1.79; 95 %CI 1.01=3.19; p=0.047). The abdominal aortic diameter in CC homozygotes of the rs7635818 polymorphism was 7.66 mm greater compared to GG homozygotes (42.5±22.0 mm vs 34.8±21.3 mm; p=0.022) and 5.88 mm greater compared to G-allele carriers (GC/GG) (42.5±22.0 mm vs 36.6±21.0 mm; p=0.04) in univariate analysis. C-allele variant in rs7635818 G>C polymorphism is associated with a higher probability of developing AAA in the Slovak population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients

Author

Zaharenko, Linda, primary, Kalnina, Ineta, additional, Geldnere, Kristine, additional, Konrade, Ilze, additional, Grinberga, Solveiga, additional, Židzik, Jozef, additional, Javorský, Martin, additional, Lejnieks, Aivars, additional, Nikitina-Zake, Liene, additional, Fridmanis, Davids, additional, Peculis, Raitis, additional, Radovica-Spalvina, Ilze, additional, Hartmane, Dace, additional, Pugovics, Osvalds, additional, Tkáč, Ivan, additional, Klimčáková, Lucia, additional, Pīrāgs, Valdis, additional, and Klovins, Janis, additional

Published
2016
Full Text
View/download PDF

19. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes

Author

Tkáč, Ivan, primary, Javorský, Martin, additional, Klimčáková, Lucia, additional, Židzik, Jozef, additional, Gaľa, Igor, additional, Babjaková, Eva, additional, Schroner, Zbynek, additional, Štolfová, Mária, additional, Hermanová, Hana, additional, and Habalová, Viera, additional

Published
2014
Full Text
View/download PDF

25. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

Author

Zhou, Kaixin, Yee, Sook Wah, Seiser, Eric L, van Leeuwen, Nienke, Tavendale, Roger, Bennett, Amanda J, Groves, Christopher J, Coleman, Ruth L, van der Heijden, Amber A, Beulens, Joline W, de Keyser, Catherine E, Zaharenko, Linda, Rotroff, Daniel M, Out, Mattijs, Jablonski, Kathleen A, Chen, Ling, Javorský, Martin, Židzik, Jozef, Levin, Albert M, Williams, L Keoki, Dujic, Tanja, Semiz, Sabina, Kubo, Michiaki, Chien, Huan-Chieh, Maeda, Shiro, Witte, John S, Wu, Longyang, Tkáč, Ivan, Kooy, Adriaan, van Schaik, Ron H N, Stehouwer, Coen D A, Logie, Lisa, Sutherland, Calum, Klovins, Janis, Pirags, Valdis, Hofman, Albert, Stricker, Bruno H, Motsinger-Reif, Alison A, Wagner, Michael J, Innocenti, Federico, Hart, Leen M 't, Holman, Rury R, McCarthy, Mark I, Hedderson, Monique M, Palmer, Colin N A, Florez, Jose C, Giacomini, Kathleen M, and Pearson, Ewan R

Abstract

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear. Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (P = 6.6 × 10−14) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry. rs8192675 was the top cis expression quantitative trait locus (cis-eQTL) for SLC2A2 in 1,226 human liver samples, suggesting a key role for hepatic GLUT2 in regulation of metformin action. Among obese individuals, C-allele homozygotes at rs8192675 had a 0.33% (3.6 mmol/mol) greater absolute HbA1c reduction than T-allele homozygotes. This was about half the effect seen with the addition of a DPP-4 inhibitor, and equated to a dose difference of 550 mg of metformin, suggesting rs8192675 as a potential biomarker for stratified medicine.

Published
2016
Full Text
View/download PDF

26. Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide.

Author

Javorský, Martin, Babjaková, Eva, Klimiáková, Lucča, Schroner, Zbynek, židzik, Jozef, Štolfová, Mária, Šalagovič, Ján, and Tkáč, Ivan

Subjects
GLICLAZIDE, PEOPLE with diabetes, TREATMENT of diabetes, SULFONYLUREAS, REVERSE transcriptase polymerase chain reaction, GLIBENCLAMIDE
Abstract

Previous studies showed associations between variants in TCF7L2 gene and the therapeutic response to sulfonylureas. All sulfonylureas stimulate insulin secretion by the closure ofATP-sensitive potassium(KATP) channel.The aim of the present study was to compare TCF7L2 genotype specific effect of gliclazide binding toKATP channel A-site (Group 1)with sulfonylureasbinding toABsite (Group 2). A total of 101 patients were treated with sulfonylureas for 6 months as an add-on therapy to the previous metformin treatment. TCF7L2 rs7903146 C/T genotype was identified by real-time PCR with subsequent melting curve analysis. Analyses using the dominant genetic model showed significantly higher effect of gliclazide in the CC genotype group in comparison with combined CT + TT genotype group (1.32 ± 0.15% versus 0.73 ± 0.11%, Padj = 0.005). No significant difference in ΔHbA1c between the patients with CC genotype and the T-allele carriers was observed in Group 2. In the multivariate analysis, only the TCF7L2 genotype (P = 0.006) and the baseline HbA1c (P < 0.001) were significant predictors of ΔHbA1c. After introducing an interaction term between the TCF7L2 genotype and the sulfonylurea type into multivariate model, the interaction became a significant predictor (P = 0.023) of ΔHbA1c. The results indicate significantly higher difference in ΔHbA1c among the TCF7L2 genotypes in patients treated with gliclazide than in patients treated with glimepiride, glibenclamide, or glipizide. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results